Ranbaxy Laboratories Release: U.K. Appeals Court Affirms Mixed High Court Of Justice's Ruling In Lipitor(R)* Case

PRINCETON, N.J., June 28 /PRNewswire/ -- Ranbaxy Laboratories Limited (Ranbaxy) today acknowledged that the U.K. Court of Appeal has handed down a decision upholding the U.K. High Court of Justice's ruling from October 12, 2005, in Ranbaxy's case against (Pfizer) Warner-Lambert over the cholesterol- lowering drug, atorvastatin, which is marketed by Pfizer as Lipitor(R). The three-judge panel confirmed that (Pfizer) Warner-Lambert's European Patent 409 281 was invalid in the U.K. However, Ranbaxy's atorvastatin product was ruled to infringe the broadest claims of (Pfizer) Warner-Lambert's European Patent 247 633 in the U.K. Ranbaxy is evaluating this decision and will decide on its course of action shortly.

Ranbaxy Laboratories Limited, headquartered in India, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies.

Ranbaxy's continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company's foray into Novel Drug Delivery Systems has led to proprietary "platform technologies," resulting in a number of products under development. The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 49 countries and manufacturing operations in 8 countries.

*Lipitor(R) is a registered trademark of Pfizer Contact details, India Contact details, USA Ranbaxy Laboratories Limited, Gurgaon Ranbaxy Inc., Princeton, NJ Media calls: Media calls: Ramesh L. Adige Chuck Caprariello +91-124-5166009 +1 609 720 5615 Mobile: +91 9810020547 Mobile: +1 609 462 7354 e-mail: ramesh.adige@ranbaxy.com e-mail: chuck.caprariello@ranbaxy.com Raghu Kochar Robert Ferris +91-124-5135141 RF Binder Partners, Inc Mobile: +91 9811617256 +1 212-994-7505 e-mail: raghu.kochar@ranbaxy.com Mobile: +1 201-888-5234 e-mail: robert.ferris@rfbinder.com Krishnan Ramalingam Anuj Baveja +91-124-5135143 RF Binder Partners, Inc Mobile: +91 9810042540 +1 212-994-7552 e-mail: krishnan.ramalingam@ranbaxy.com Mobile: +1 551-587-2233 e-mail: anuj.baveja@rfbinder.com Analysts and investors: Contact details, Europe Anurag Kalra Stonehenge Public Relations +91-124-5135163 Ltd., London Mobile: +91 9810109253 Media calls: e-mail: anurag.kalra@ranbaxy.com Geoff Potter +44 [0] 207 434 2255 Mobile: +44 [0] 7802 292044 e-mail: geoff@stonehengepr.com

CONTACT: Contact details, India, Ranbaxy Laboratories Limited, Gurgaon:Media calls: Ramesh L. Adige, +91-124-5166009, Mobile: +91-9810020547,ramesh.adige@ranbaxy.com, or Raghu Kochar, +91-124-5135141, Mobile:+91-9811617256, raghu.kochar@ranbaxy.com, or Krishnan Ramalingam,+91-124-5135143, Mobile: +91-9810042540, krishnan.ramalingam@ranbaxy.com,or Analysts and investors: Anurag Kalra, +91-124-5135163, Mobile:+91-9810109253, anurag.kalra@ranbaxy.com; or Contact details, USA, RanbaxyInc., Princeton, NJ, Media calls: Chuck Caprariello, +1-609-720-5615,Mobile: +1-609-462-7354, chuck.caprariello@ranbaxy.com, or Robert Ferris,RF Binder Partners, Inc, +1-212-994-7505, Mobile: +1-201-888-5234,robert.ferris@rfbinder.com, or Anuj Baveja, RF Binder Partners, Inc,+1-212-994-7552, Mobile: +1-551-587-2233, anuj.baveja@rfbinder.com; orContact details, Europe, Stonehenge Public Relations Ltd., London, Mediacalls: Geoff Potter, +44-[0]-207-434-2255, Mobile: +44-[0]-7802-292044,e-mail: geoff@stonehengepr.com

Web site: http://www.ranbaxy.com/